Literature DB >> 31123972

Extracellular Matrix Fragments of the Basement Membrane and the Interstitial Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis.

Majken Lindholm1,2, Tina Manon-Jensen3, Gunvor Iben Madsen4, Aleksander Krag5, Morten Asser Karsdal3, Jens Kjeldsen5, Joachim Høg Mortensen3.   

Abstract

BACKGROUND: Chronic intestinal inflammation results in tissue damage partly caused by an increase in matrix metalloproteinases (MMP) activity causing degradation of extracellular matrix (ECM) proteins. We studied intestinal tissue remodeling by quantifying ECM protein fragments in serum in dextran sulfate sodium (DSS)-induced colitis, to investigate ECM protein fragments as serological biomarkers of intestinal tissue remodeling and disease activity.
METHODS: Male Sprague-Dawley rats received 5% DSS in drinking water for 5 days followed by 11 days with regular water. Disease activity index (DAI) was scored daily. Serum was collected on day 0, 6, 7, and 16. ELISAs were used to quantify MMP-derived remodeling fragments of basement membrane type IV collagen (C4M and PRO-C4) and interstitial matrix type III collagen (C3M and rPRO-C3).
RESULTS: In DSS rats, serum levels relative to baseline of C4M, PRO-C4, and C3M were elevated (P < 0.01; P < 0.001; P < 0.001) at day 7, which declined at day 16. Levels of rPRO-C3 were lower in DSS rats at day 7 and increased to normal levels at day 16. The ratio between C3M and rPRO-C3 showed an overall degradation (P < 0.0001) of collagen type III in DSS rats at day 7, which correlated to the DAI (r2 = 0.5588, P < 0.0001).
CONCLUSION: Our data suggest that remodeling of the basement membrane (C4M and PRO-C4) and the interstitial matrix (C3M and rPRO-C3) increased during DSS-induced colitis and declined with reversal of the disease. Thus, serological biochemical biomarkers of the ECM reflect tissue remodeling and could be studied as markers of disease activity in IBD.

Entities:  

Keywords:  Collagens; DSS-induced colitis; Extracellular matrix remodeling; Inflammatory bowel disease; Serological biomarkers

Year:  2019        PMID: 31123972     DOI: 10.1007/s10620-019-05676-6

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

Review 1.  Emerging role of novel biomarkers in the diagnosis of inflammatory bowel disease.

Authors:  Anet A Soubières; Andrew Poullis
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

Review 2.  Wound healing and fibrosis in intestinal disease.

Authors:  F Rieder; J Brenmoehl; S Leeb; J Schölmerich; G Rogler
Journal:  Gut       Date:  2007-01       Impact factor: 23.059

3.  Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.

Authors:  B von Lampe; B Barthel; S E Coupland; E O Riecken; S Rosewicz
Journal:  Gut       Date:  2000-07       Impact factor: 23.059

4.  Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease.

Authors:  T Kirkegaard; A Hansen; E Bruun; J Brynskov
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

5.  Attenuation of dextran sodium sulphate induced colitis in matrix metalloproteinase-9 deficient mice.

Authors:  Alfredo Santana; Carlos Medina; Maria-Cristina Paz-Cabrera; Federico Díaz-Gonzalez; Esther Farré; Antonio Salas; Marek-W Radomski; Enrique Quintero
Journal:  World J Gastroenterol       Date:  2006-10-28       Impact factor: 5.742

6.  Dextran sulphate sodium induces acute colitis and alters hepatic function in hamsters.

Authors:  Agneta Karlsson; Ake Jägervall; Madeleine Pettersson; Ann-Katrin Andersson; Per-Göran Gillberg; Silvia Melgar
Journal:  Int Immunopharmacol       Date:  2007-10-29       Impact factor: 4.932

7.  Serum laminin and collagen IV in inflammatory bowel disease.

Authors:  I E Koutroubakis; E Petinaki; P Dimoulios; E Vardas; M Roussomoustakaki; A N Maniatis; E A Kouroumalis
Journal:  J Clin Pathol       Date:  2003-11       Impact factor: 3.411

Review 8.  ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation.

Authors:  Elee Shimshoni; Doron Yablecovitch; Liran Baram; Iris Dotan; Irit Sagi
Journal:  Gut       Date:  2014-11-21       Impact factor: 23.059

9.  Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease.

Authors:  W T van Haaften; J H Mortensen; M A Karsdal; A C Bay-Jensen; G Dijkstra; P Olinga
Journal:  Aliment Pharmacol Ther       Date:  2017-05-08       Impact factor: 8.171

10.  Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks.

Authors:  Woo-Jeong Shon; Young-Kwan Lee; Ji Hee Shin; Eun Young Choi; Dong-Mi Shin
Journal:  Sci Rep       Date:  2015-11-27       Impact factor: 4.379

View more
  10 in total

1.  Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.

Authors:  Amy C Porter; Jiri Aubrecht; Chandler Birch; Jonathan Braun; Carolyn Cuff; Suryasarathi Dasgupta; Jeremy D Gale; Robert Hinton; Steven C Hoffmann; Gerard Honig; Bryan Linggi; Marco Schito; Niels Vande Casteele; John-Michael Sauer
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

2.  Endotrophin and C6Ma3, serological biomarkers of type VI collagen remodelling, reflect endoscopic and clinical disease activity in IBD.

Authors:  Majken Lindholm; Line E Godskesen; Tina Manon-Jensen; Jens Kjeldsen; Aleksander Krag; Morten A Karsdal; Joachim H Mortensen
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

Review 3.  Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives.

Authors:  Chunhua Yang; Didier Merlin
Journal:  Int J Nanomedicine       Date:  2019-11-13

4.  Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn's Disease.

Authors:  Marta S Alexdottir; Arno R Bourgonje; Morten A Karsdal; Martin Pehrsson; Roberta Loveikyte; Hendrik M van Dullemen; Marijn C Visschedijk; Eleonora A M Festen; Rinse K Weersma; Klaas Nico Faber; Gerard Dijkstra; Joachim H Mortensen
Journal:  Int J Mol Sci       Date:  2022-07-23       Impact factor: 6.208

5.  Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn's Disease.

Authors:  Marta S Alexdottir; Arno R Bourgonje; Morten A Karsdal; Martin Pehrsson; Roberta Loveikyte; Hendrik M van Dullemen; Marijn C Visschedijk; Eleonora A M Festen; Rinse K Weersma; Klaas Nico Faber; Gerard Dijkstra; Joachim H Mortensen
Journal:  Front Med (Lausanne)       Date:  2022-07-12

6.  A Specific Calprotectin Neo-epitope [CPa9-HNE] in Serum from Inflammatory Bowel Disease Patients Is Associated with Neutrophil Activity and Endoscopic Severity.

Authors:  Joachim Høg Mortensen; Dovile Sinkeviciute; Tina Manon-Jensen; Viktor Domislović; Kathryn McCall; Christian S Thudium; Marko Brinar; Patrik Önnerfjord; Carl S Goodyear; Željko Krznarić; Morten Asser Karsdal; Anne-Christine Bay-Jensen
Journal:  J Crohns Colitis       Date:  2022-09-08       Impact factor: 10.020

7.  Inflammatory Biomarkers of Extracellular Matrix Remodeling and Disease Activity in Crohn's Disease and Ulcerative Colitis.

Authors:  Viktor Domislovic; Joachim Høg Mortensen; Majken Lindholm; Morten Asser Kaarsdal; Marko Brinar; Ana Barisic; Tina Manon-Jensen; Zeljko Krznaric
Journal:  J Clin Med       Date:  2022-10-07       Impact factor: 4.964

8.  Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohn's disease.

Authors:  Arno R Bourgonje; Marta S Alexdottir; Antonius T Otten; Roberta Loveikyte; Anne-Christine Bay-Jensen; Martin Pehrsson; Hendrik M van Dullemen; Marijn C Visschedijk; Eleonora A M Festen; Rinse K Weersma; Morten A Karsdal; Klaas Nico Faber; Joachim H Mortensen; Gerard Dijkstra
Journal:  Aliment Pharmacol Ther       Date:  2022-06-06       Impact factor: 9.524

Review 9.  Bacterial Involvement in Progression and Metastasis of Adenocarcinoma of the Stomach.

Authors:  Amanda D Morgan; Kevin D Seely; Lauren D Hagenstein; Garrett M Florey; James M Small
Journal:  Cancers (Basel)       Date:  2022-10-06       Impact factor: 6.575

10.  Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn's disease.

Authors:  T Manon-Jensen; S Sun; M Lindholm; V Domislović; P Giuffrida; M Brinar; G Mazza; M Pinzani; Z Krznarić; A Di Sabatino; M A Karsdal; J H Mortensen
Journal:  United European Gastroenterol J       Date:  2021-03-29       Impact factor: 4.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.